Osteonecrosis of the jaw (ONJ) has been associated with the use of pamidronate and zoledronic acid. ONJ was assessed prospectively since July 2003 in 202 patients with multiple myeloma (MM) who received bisphosphonates since April 1995. Fifteen patients (7.4%) developed ONJ. The median time of exposure to bisphosphonates was 39 months for patients with ONJ compared to 28 months (p=0.048) for patients with no ONJ. The cumulative hazard of developing ONJ was significantly higher in patients treated with zoledronic acid alone than in those treated with pamidronate alone/pamidronate+zoledronic acid/zoledronic acid+ibandronate sequentially (1% at 1 year and 15% at 4 years vs. 0% and 5%, p=0.003). In conclusion, the risk of ONJ is increased with time of exposure and probably with the use of zoledronic acid.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hajdu-Cheney Syndrome, a Rare Cause of Acro-Osteolysis and Osteoporosis With Zoledronic Acid Experience.
Am J Med Genet A
January 2025
Department of Pediatric Genetics, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
Hajdu-Cheney syndrome (HCS), caused by a heterozygous gain of function variant of the NOTCH2 gene, is a rare skeletal dysplasia. Although the main presentation is acro-osteolysis, osteoporosis, and facial dysmorphism, having a wide range of clinical manifestations creates diagnostic difficulties. Here, a 15-year-old male patient with HCS who had no complaints until this age except for two short bone fractures and one vertebral collapse fracture due to a fall was reported.
View Article and Find Full Text PDFArticle Synopsis
- Relapsing polychondritis (RP) is a rare autoimmune disorder that causes recurring inflammation in cartilaginous tissues, affecting areas like the ears, nose, and joints.
- A 68-year-old woman without prior health issues showed symptoms like hoarseness, polyarthritis, and nasal/ear involvement, leading to her RP diagnosis using the Modified McAdam criteria.
- She was treated with intravenous cyclophosphamide and oral prednisolone, which improved her condition, while osteoporosis was treated with zoledronic acid, highlighting RP's role in patient assessments involving similar symptoms.
Zoledronic acid as adjuvant therapy in neovascular age-related macular degeneration: a randomised controlled pilot study.
BMJ Open Ophthalmol
December 2024
Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.
Article Synopsis
- The study aimed to evaluate the feasibility of using zoledronic acid (ZA) as a supplementary treatment for neovascular age-related macular degeneration (nAMD) in a randomized controlled trial.
- A total of 40 nAMD patients were split into two groups, with one receiving ZA and the other a placebo, and the primary focus was on changes in visual acuity after treatment.
- Results showed that the group receiving ZA had improved visual acuity compared to the placebo group, suggesting potential benefits that warrant further exploration, although the small sample size limits the strength of these findings.
Identification of genetic associations between acute myocardial infarction and non-small cell lung cancer.
Front Mol Biosci
December 2024
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Article Synopsis
- Research indicates a potential link between myocardial infarction (MI) and lung cancer (LC), with an aim to uncover shared genes and pathways through bioinformatics analysis.
- Two public datasets were analyzed to find differentially expressed genes (DEGs), with enrichment analysis revealing connections to key biological processes and the identification of eight hub genes that show diagnostic promise.
- Eight common signature genes linked to both diseases were validated, and zoledronic acid was highlighted as a potential therapeutic drug for treating patients suffering from both MI and LC.
Synthetic inhibition of SREBP2 and the mevalonate pathway blocks rhabdomyosarcoma tumor growth in vitro and in vivo and promotes chemosensitization.
Mol Metab
December 2024
Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. Electronic address:
Article Synopsis
- The study aimed to explore the effects of targeting the mevalonate pathway (MVP) in rhabdomyosarcoma (RMS), a common soft tissue tumor in young individuals.
- In silico analyses showed that higher levels of MVP-related genes correlated with poorer patient survival, while in vitro tests revealed that MVP inhibitors significantly reduced RMS cell growth, migration, and survival.
- In vivo experiments demonstrated the effectiveness of MVP inhibition in RMS xenografts, highlighting the potential of these inhibitors as a therapeutic strategy against RMS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!